AI Article Synopsis
- Venous Ulcers (VU) are a common type of leg ulcer caused by problems like venous hypertension or valve failure, making up 60-80% of all cases.
- While traditional treatment methods that target the underlying causes are standard, about 30% of these ulcers don't heal with those approaches, leading to the exploration of growth factors as additional treatments.
- A review of various studies from 2002 to 2022 found that topical, intralesional, and perilesional applications of growth factors could be effective, with the latter suggesting a promising alternative treatment for venous ulcers.
Article Abstract
Venous Ulcers (VU) represent 60-80% of all leg ulcers and are the final stage of the disease secondary to venous hypertension or valve insufficiency. Conventional treatment that focuses on its etiological factors continues to be the gold standard; however, 30% of ulcers do not heal with this treatment; thus, it has been seen that the use of growth factor can be used as an adjuvant for this pathology. A literature review was carried out to evaluate the evidence from systematic reviews, meta-analyses, case studies, and quantitative studies that respond to the objective of this analysis review in the different databases with specific inclusion criteria with publications between 2002 and 2022, initially finding the topical application of the factor and later, more recently, the intralesional and perilesional application, the latter being an alternative treatment for this type of pathology and generating some recommendations for using the Factor.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494861 | PMC |
| http://dx.doi.org/10.2147/VHRM.S417447 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!